929 related articles for article (PubMed ID: 19379588)
21. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
22. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
Li JM; Shen Y; Wu DP; Liang H; Jin J; Chen FY; Song YP; Song EY; Qiu XF; Hou M; Qiu ZC; Shen ZX
Int J Hematol; 2005 Jul; 82(1):48-54. PubMed ID: 16105759
[TBL] [Abstract][Full Text] [Related]
23. [The potential prognostic influence of granulocyte-colony stimulating factor in acute leukemia].
Liu XM; Chen YZ; Huang MJ; Liu X; Guo JR
Zhonghua Nei Ke Za Zhi; 2005 Jul; 44(7):518-21. PubMed ID: 16080844
[TBL] [Abstract][Full Text] [Related]
24. [Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in 50 patients with relapsed acute myeloid leukemia].
Zhu BG; Qian SX; Hong M; Lu H; Wu HX; Zhang SJ; Qiu HX; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):760-4. PubMed ID: 19549403
[TBL] [Abstract][Full Text] [Related]
25. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
[TBL] [Abstract][Full Text] [Related]
26. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; Walter RB; Parks C; Wood BL; Abkowitz JL; Estey EH
Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Estey EH; Thall PF; Pierce S; Cortes J; Beran M; Kantarjian H; Keating MJ; Andreeff M; Freireich E
Blood; 1999 Apr; 93(8):2478-84. PubMed ID: 10194425
[TBL] [Abstract][Full Text] [Related]
28. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
[TBL] [Abstract][Full Text] [Related]
29. [Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes].
Zhang YP; Wu WZ; Cui GX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1341-4. PubMed ID: 25338585
[TBL] [Abstract][Full Text] [Related]
30. [Efficiency of GHA priming chemotherapy on patients with refractory acute myeloid leukemia and myelodysplastic syndrome and its relationship with expression of costimulatory molecule B7.1].
Chen YX; Ma XR; Zhang WG; Liu J; Cao XM; He AL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1002-5. PubMed ID: 18928583
[TBL] [Abstract][Full Text] [Related]
31. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
32. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
33. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
34. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
[TBL] [Abstract][Full Text] [Related]
35. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.
Wei G; Ni W; Chiao JW; Cai Z; Huang H; Liu D
J Hematol Oncol; 2011 Nov; 4():46. PubMed ID: 22082134
[TBL] [Abstract][Full Text] [Related]
36. Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia.
Liu L; Zhang Y; Jin Z; Zhang X; Zhao G; Si Y; Lin G; Ma A; Sun Y; Wang L; Wu D
Int J Hematol; 2014; 99(5):603-8. PubMed ID: 24623261
[TBL] [Abstract][Full Text] [Related]
37. [The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].
Gao S; Qiu H; Jin Z; Tang X; Fu Z; Ma X; Han Y; Chen S; Sun A; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):961-5. PubMed ID: 25417868
[TBL] [Abstract][Full Text] [Related]
38. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
Qu Q; Liu L; Zhang Y; Li X; Wu D
Leuk Res; 2015 Dec; 39(12):1353-9. PubMed ID: 26432074
[TBL] [Abstract][Full Text] [Related]
39. [FLAG regimen as consolidation therapy for patients with acute myeloid leukemia].
Qian SX; Wu HX; Hong M; Lu H; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1577-81. PubMed ID: 20030951
[TBL] [Abstract][Full Text] [Related]
40. Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.
Zhu HH; Jiang H; Jiang B; Lu J; Jiang Q; Bao L; Zhang XH; Qin YZ; Huang XJ
Leuk Lymphoma; 2013 Nov; 54(11):2452-7. PubMed ID: 23432721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
